A record of what Jefferies Analysis said publicly, with the source. Not advice.
Pending — not yet graded
“Upgraded Gland Pharma to 'Hold' from 'Underperform', raising the price target to ₹1,950 from ₹1,350. The firm believes Gland Pharma's earnings have bottomed out, with Cenexi achieving EBITDA breakeven, despite soft US performance. Full-year guidance remains strong, expecting mid-teens growth.”
Jefferies Analysis’s track record (trackable calls only): 153 graded calls · 95% CI 37–53%
Gland PharmaNeutralCalled 06 Aug 2025
This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.
Read the original articleSee Jefferies Analysis’s full track record